A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1

Narayanan, Raja; Panchal, Bhavik; Das, Taraprasad; Chhablani, Jay; Jalali, Subhadra; Ali, Mohammed

doi:10.1136/bjophthalmol-2014-306543

Cited by 86 publications

(82 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…From a functional point of view, the percentage of patients with CRVO and visual loss greater than 15 letters has been noted in 5% of the patients after treatment by aflibercept [31], 6% for bevacizumab [32] and 3-12% for ranibizumab [33,34]. Failure has also been reported in cases when rescue laser treatment was prescribed in BRVO patients for persistent diffuse oedema in 10% of the ranibizumab group and 21% of the bevacizumab group in the MARVEL study [35] and in 20% after ranibizumab [34]. Recalcitrant ME in patients treated with anti-VEGF has been previously associated with systemic hypertension and more retinal ischaemia [36,37].…”

Section: Discussionmentioning

confidence: 99%

Retinal Vein Occlusions: Therapeutic Switch in Macular Oedema Treatment with a 12-Month Follow-Up

Chiquet¹,

Bron²,

Straub³

et al. 2016

Ophthalmic Res

View full text Add to dashboard Cite

Purpose: To compare the visual and anatomical outcomes of patients with macular oedema secondary to retinal vein occlusion (RVO) after a switch from bevacizumab to intravitreal injection of a dexamethasone implant (IVI-DEX) or conversely. Methods: 48 patients - 40 in the antivascular endothelial growth factor (VEGF) DEX sequence (AD group), 8 in the DEX anti-VEGF sequence (DA group) - were included in this multicentre retrospective study and evaluated at baseline, 1, 3, 6 and 12 months after the switch. The outcome measurements were visual acuity (VA) and central macular thickness (CMT) evaluated by spectral domain optical coherence tomography. Patients were defined as ‘good responders' if CMT was ≤ 300 µm after the switch. Results: VA significantly improved at 1 month in the AD group (p = 0.03) but not in the DA group (p = 0.40). CMT decreased significantly in the AD group at 1, 6 and 12 months (p = 0.002, p = 0.005 and p = 0.002, respectively). In the DA group, VA did not change from baseline at any time point, and CMT decreased at 1 month (p = 0.02) but not later on. Conclusions: In patients with macula oedema secondary to RVO, the switch from bevacizumab to IVI-DEX seems more beneficial in terms of short-term VA and long-term reduction of CMT than the DEX anti-VEGF agent sequence.

show abstract

Section: Discussionmentioning

confidence: 99%

Retinal Vein Occlusions: Therapeutic Switch in Macular Oedema Treatment with a 12-Month Follow-Up

Chiquet¹,

Bron²,

Straub³

et al. 2016

Ophthalmic Res

View full text Add to dashboard Cite

show abstract

“…Using a fixed dosing regimen of monthly injections for a set period, all studies demonstrated aflibercept and ranibizumab as effective treatments for macular oedema from BRVO and CRVO respectively with low local and systemic safety issues identified. Clinical studies have further shown anti-VEGF agent bevacizumab to be of similar efficacy in reducing macular thickness and improving visual acuity (VA) 2 9…”

Section: Introductionmentioning

confidence: 99%

Impact of initial visual acuity on anti-VEGF treatment outcomes in patients with macular oedema secondary to retinal vein occlusions in routine clinical practice

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Ranibizumab is a recombinant humanized monoclonal antibody fragment. Clinically it was demonstrated to alleviate macular edema, and reduce neovascularization and vascular leakage in patients by effectively antagonizing VEGF (13,14). In this study, the levels of VEGF in rat serum and aqueous humor were determined, and it was found that the VEGF levels of rats treated with ranibizumab were significantly lower (P<0.05) than those of the control group, and decreased further over time in the treatment.…”

Section: Discussionmentioning

confidence: 99%

Effect of ranibizumab on levels of IL-6 and VEGF in peripheral blood and aqueous humor of glaucoma rat model and association of IL-6 and VEGF with optic nerve damage

Song

et al. 2018

Exp Ther Med

View full text Add to dashboard Cite

This study aims to investigate the effect of intravitreal injection of ranibizumab on glaucoma rat model and its effect on optic nerve injury. A total of 125 SD rats were used to establish glaucoma models. Of them, 80 well-established model were selected, 40 of which received intravitreal injections of ranibizumab and were assigned to the observation group. The remaining 40 received no drug and were assigned to the control group. After rats were sacrificed at the time-points, the retina was harvested. Numbers of retinal ganglion cells (RGCs) were counted under a fluorescence microscope. In the meantime, levels of interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) in peripheral blood and aqueous humor were determined. The levels of IL-6 and VEGF in peripheral blood and aqueous humor decreased gradually over the time of treatment in the observation group (P<0.05). In the control group the levels of IL-6 in peripheral blood and aqueous humor increased gradually over time (P<0.05). At the same time-point, the IL-6 level was higher in the control group than that in the observation group (P<0.05). The VEGF level in the observation group was lower in day 21 than that in day 7 (P<0.05). The VEGF level was higher in the control group than that in the observation group (P<0.05). The number of RGCs in the observation group increased gradually over the time of treatment, and there were significant differences in the number of RGCs between day 7 and 14, as well as day 14 and 21 (P<0.05). The number of RGCs in the control group decreased gradually over time (P<0.05). The levels of IL-6 and VEGF were all negatively correlated with the number of RGCs, and the correlation coefficient r and P-value were −0.743 and 0.012, and −0.675 and 0.022, respectively. Ranibizumab attenuated optic nerve injury by reducing levels of IL-6 and VEGF in peripheral blood and aqueous humor of glaucoma rat model.

show abstract

A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1

Abstract: http://www.ctri.nic.in/ CTRI/2012/01/003120.

Cited by 86 publications

References 20 publications

Retinal Vein Occlusions: Therapeutic Switch in Macular Oedema Treatment with a 12-Month Follow-Up

Retinal Vein Occlusions: Therapeutic Switch in Macular Oedema Treatment with a 12-Month Follow-Up

Impact of initial visual acuity on anti-VEGF treatment outcomes in patients with macular oedema secondary to retinal vein occlusions in routine clinical practice

Effect of ranibizumab on levels of IL-6 and VEGF in peripheral blood and aqueous humor of glaucoma rat model and association of IL-6 and VEGF with optic nerve damage

Contact Info

Product

Resources

About